Researchers find programme that could improve IVF outcomes
Women with obesity who are planning a pregnancy are already advised that losing weight can improve their chances of conceiving. Our research suggests that structured weight loss support may also improve outcomes for those seeking IVF.
Our study analysed data from 12 international trials involving 1,921 women living with obesity, all planning IVF. It compared those offered a weight loss programme before IVF with those receiving standard care, which typically does not include such support.
Women who took part in a weight loss programme had a 21% higher chance of becoming pregnant overall – whether naturally or through IVF. The biggest difference was in natural conceptions: the likelihood of getting pregnant without IVF rose by 47%, meaning some women avoided fertility treatment altogether.
However, despite these higher pregnancy rates and no increase in miscarriage risk, there was no clear evidence of an effect on live birth rates. This may be because many of the included studies didn't track live birth outcomes – even though this is the result that matters most to patients.
IVF access paradox
In the UK, publicly funded IVF is restricted to women with a BMI under 30. Similar weight-based eligibility rules exist in many other countries. These policies disproportionately affect women from more deprived backgrounds and some ethnic groups, who are more likely to be living with obesity.
The paradox is clear: women with obesity are more likely to need IVF, but less likely to be eligible for it.
Some can afford private weight loss programmes to meet the BMI requirement. Others resort to unproven or unsafe methods to lose weight quickly, risking their health in order to access fertility care.
Our research findings suggest that offering structured weight loss programmes to women with obesity who are otherwise ineligible for IVF could help more women become pregnant – and in some cases avoid IVF altogether.
This approach could also make fertility treatment more equitable. Since the cost of weight loss support is relatively low compared with IVF, including it in the treatment pathway might offer better value for healthcare providers.
Weight loss options before IVF
The most effective non-surgical option for significant weight loss is a class of medications called GLP-1 receptor agonists – such as Wegovy or Mounjaro – which have been shown to lead to substantial weight reduction.
However, these drugs should not be used during pregnancy, while trying to conceive, or while breastfeeding, as there's little safety data in humans – and animal studies suggest potential harm to foetal development. Anyone who becomes pregnant while taking GLP-1 drugs should stop immediately and consult a healthcare professional.
For women planning to conceive soon, there are other safe and effective options, including structured support groups and low-energy diet programmes. The problem is that such services are not offered as part of standard IVF care.
While some NHS weight management programmes exist, access is limited, waiting lists can be long, and most are aimed at people with obesity-related health conditions rather than those seeking fertility treatment. In many other countries, insurance coverage for weight loss support is similarly patchy, meaning these services must often be funded privately – a cost that can put them out of reach for those who could benefit most.
The message from this research is clear: targeted, supportive weight loss programmes before IVF don't just improve pregnancy chances – they could also reduce the need for IVF, promote fairer access to fertility treatment, and save healthcare resources. The challenge now is making sure they're available to everyone who needs them, not just those who can afford to pay.
Nerys M. Astbury is an Associate Professor in Health Behaviours at the University of Oxford.
Moscho Michalopoulou is a Behavioural Scientist in the Nuffield Department of Primary Care Health Sciences at the University of Oxford.
Pedro Melo is an NIHR Academic Clinical Lecturer in Obstetrics & Gynaecology in the Nuffield Department of Women's and Reproductive Health at the University of Oxford.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
28 minutes ago
- Fast Company
Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases. Lilly currently dominates the obesity treatment market, which is estimated to be worth $150 billion by the next decade, and is trying to strengthen its foothold in the space through the development of next-generation drugs, acquisitions and partnerships. The deal gives Lilly access to Superluminal's proprietary artificial-intelligence-driven platform to rapidly discover potential drug candidates targeting G-protein-coupled receptors (GPCR)—a class of proteins that can influence a range of physiological processes including metabolism, cell growth and immune responses—the drug developer said on Thursday. In a similar move, Danish rival Novo Nordisk struck a $2.2 billion deal with U.S. biotech Septerna in May to develop oral small-molecule medicines targeting GPCRs for obesity and other cardiometabolic diseases. Lilly has been capitalizing on the overwhelming popularity of the GLP-1 class of medicines, which includes its blockbuster drug Zepbound as well as Novo's Wegovy. It is also developing a keenly watched oral GLP-1 drug, orforglipron, which has failed to meet investors' lofty expectations. The drugmaker teamed up with Hong Kong-listed biotech Laekna last year to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle. Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's platform, the drug developer said. As part of the deal, Superluminal is eligible to receive upfront and milestone payments, an equity investment as well as tiered royalties on net sales, the company said. Boston-based startup Superluminal is developing a wholly owned lead candidate targeting a protein called melanocortin 4 receptor to treat certain rare, genetic forms of obesity and is expected to begin human trials next year. The lead candidate is not part of the deal with Lilly. Superluminal is backed by investors including RA Capital Management, Insight Partners and NVentures, NVIDIA's venture capital arm.
35 minutes ago
Got the sniffles? Here's what to know about summer colds and the COVID-19 variant called stratus
Summer heat, outdoor fun ... and cold and flu symptoms? The three may not go together in many people's minds: partly owing to common myths about germs and partly because many viruses really do have lower activity levels in the summer. But it is possible to get the sniffles — or worse — in the summer. Federal data released Friday, for example, shows COVID-19 is trending up in most states, with emergency department visits up among people of all ages. Here's what to know about summer viruses. The number of people seeking medical care for three key illnesses — COVID-19, flu and respiratory syncytial virus, or RSV — is currently very low, according to data from the Centers for Disease Control and Prevention. Flu is trending down and RSV has been steady. But COVID-19 is trending up in most U.S. states. Wastewater data from around the country estimates 'moderate' COVID-19 activity. CDC wastewater also shows the XFG variant — nicknamed stratus — is most common in the U.S. Stratus can cause a 'razor blade' sore throat and is considered a 'variant under monitoring' by the World Health Organization. The WHO said the variant is only marginally better at evading people's immune systems and vaccines still work against it. The expectation is that COVID-19 will eventually settle into a winter seasonal pattern like other coronaviruses, but the past few years have brought a late summer surge, said Dr. Dean Blumberg, chief of pediatric infectious diseases at University of California Davis Children's Hospital. Other viruses circulating this time of year include the one that causes 'hand, foot and mouth' disease — which has symptoms similar to a cold, plus sores and rashes — and norovirus, sometimes called the stomach flu. Many viruses circulate seasonally, picking up as the weather cools in the fall and winter. So it's true that fewer people get stuffy noses and coughs in the summer — but cold weather itself does not cause colds. It's not just about seasonality. The other factor is our behavior, experts say. Nice weather means people are opening windows and gathering outside where it's harder for germs to spread. But respiratory viruses are still around. When the weather gets too hot and everyone heads inside for the air conditioning, doctors say they start seeing more sickness. In places where it gets really hot for a long time, summer can be cold season in its own right. 'I grew up on the East Coast and everybody gets sick in the winter,' said Dr. Frank LoVecchio, an emergency room doctor and Arizona State University researcher. 'A lot of people get sick in the summer here. Why is that? Because you spend more time indoors.' For people who are otherwise healthy, timing is a key consideration to getting any vaccine. You want to get it a few weeks before that big trip or wedding, if that's the reason for getting boosted, doctors say. But, for most people, it may be worth waiting until the fall in anticipation of winter cases of COVID-19 really tick up. 'You want to be fully protected at the time that it's most important for you,' said Dr. Costi Sifri, of the University of Virginia Health System. People at higher risk of complications should always talk with their doctor about what is best for them, Sifri added. Older adults and those with weak immune systems may need more boosters than others, he said. Last month, the CDC noted emergency room visits among children younger than 4 were rising. That makes sense, Blumberg said, because many young kids are getting it for the first time or are unvaccinated. Health Secretary Robert F. Kennedy Jr. said in May that the shots would no longer be recommended for healthy kids, a decision that health experts have said lacks scientific basis. The American Academy of Pediatrics still endorses COVID-19 shots for children older than 6 months. The same things that help prevent colds, flu and COVID any other time of the year work in the summer, doctors say. Spend time outside when you can, wash your hands, wear a mask. And if you're sick, stay home. ___
Yahoo
an hour ago
- Yahoo
We weren't actually more anxious during Covid, researchers discover
You weren't actually more anxious during the Covid pandemic. Scientists say that anxiety levels among U.S. adults appear to have stayed steady during that period, with new research challenging the belief that there was a widespread spike in psychological distress. Previous research had found a 25 percent increase in the prevalence of anxiety and depression, which the World Health Organization said was linked to feelings of loneliness and fear of infection during the pandemic. The new research, which surveyed nearly 100,000 U.S. adults between 2011 and 2022, found that there was no prolonged spike in anxiety levels for younger or older adults. 'Our results might suggest that the mental health of U.S. adults is more resilient than public perception suggests, given the many news headlines about the U.S. currently experiencing a 'mental health crisis,'' Noah French, a researcher at University of Virginia and an author of the new study, explained in a statement. The pandemic was cited by Biden administration officials as worsening America's mental health crisis in 2023, and the Centers for Disease Control and Prevention now says nearly one in four U.S. adults report having a mental illness. Some 38 percent more people had been in mental health care since the onset of the pandemic, researchers said. The pandemic disproportionately affected the mental health of younger adults, WHO has reported. The isolating impact of school closures also resulted in anxious kids who were academically behind their peers, according to an analysis in The New York Times, and dozens of related studies. However, the new study found that while those aged 18-25 showed significantly stronger symptoms of anxiety compared to older adults during the pandemic, young adults' anxiety levels did not increase from 2011 to 2022 overall. The reasons behind these observations in younger and older adults are unclear. Other surveys have found that Americans are feeling more anxious in general. Polling data from last year found that 43 percent of U.S. adults felt more anxious than they did the previous year and in 2022, according to the American Psychiatric Association. This uptick in American anxiety stems from current events, the economy, and gun violence, the association said. And of the more than 2,200 adults surveyed, 63 percent said they were anxious about their health. It's also possible that worsening mental health was the reason Americans drank more alcohol during the pandemic, according to doctors. One study suggested that mothers with young children drank 300 percent more alcohol than they did before Covid. French said that more research is needed to fully understand what happened, and cautioned against drawing firm conclusions on anxiety levels from his findings. For one, participants skewed younger, were more educated, and had all signed up to answer the questions. That means that they might not be entirely representative of the average American. 'One of my biggest personal takeaways from this project is that there is surprisingly little high-quality research tracking the mental health of entire populations over time,' French said. 'We need a lot more research in this space, and I will forever be skeptical of headlines that make strong claims about a certain mental health condition being 'on the rise.''
